Skip to main content

Webinar: Biotherapeutic Development is Hard: ProteinSimple Delivers Tools to Simplify the Process

Webinar Summary

In order to bring an antibody or other biologic drug to market, each step of the process needs to be carefully monitored. Charge heterogeneity and apparent MW via SDS-PAGE are two of the most commonly assessed parameters. Ideally, similar methods should be used from the beginning of development (low expression, complex matrix) to late in production and QC (high concentration, pure material). This enables comparison of early development findings to product release data.

Capillary-based techniques such as iCE and CE-SDS are currently heavily used in downstream product development, but pose challenges for small scale screening and characterization during cell culture and formulation development. In this webinar, we will discuss the latest Simple Western™ product, Peggy, which combines capillary electrophoresis with an immunoassay to provide highly reproducible and fully automated analysis of monoclonal antibodies.

This sensitive instrument measures either size or charge in complex samples and provides critical charge heterogeneity, size, and product titer information without the need for sample purification. Data will be presented demonstrating the complementarity of the Simple Western assay and the iCE technology for the analysis of monoclonal antibodies against VEGF and the ability of the two techniques to provide consistency of data across a product development program.



John Proctor, Ph.D., Director, Corporate Development, ProteinSimple